A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Study Number:EA6134
IRB Number:788089
Trial Type:Oncology - Melanoma & Skin
Trial Status:Open to Accrual
Date Posted:09/14/2015
Principal Investigator:Mei Tang, MD
Contact Name:Kathryn Tower
Fax:(443) 849-3777

For more details on this study, please refer to the Clinicaltrials.gov website at the link below:


IMPORTANT Visitor Policy Changes

Recent Stories
In the Media